The rapid course of small cell lung cancer and treatment options - case report
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.060Keywords
small cell lung cancer, treatment, survival outcomesAbstract
Small cell lung cancer (SCLC) is a disease with an unfavorable prognosis. Factors contributing to losing prognosis include: systemic disease, many comorbidities, smoking and the patient's low performance status (PS). Early diagnosis and treatment initiation seem to be the most significant in the diagnostic and therapeutic process. However, most of patients are diagnosed in metastatic stage. The basic method of metastatic SCLC treatment is chemotherapy, which, according to the latest research (CASPIAN, IMPower133), can be linked to immunotherapy, which is associated with a major improvement in therapeutic efficiency. We present a case of 64-year-old man with a rapidly progressive course of small cell lung cancer, where the fulminant course of the disease led to death within about one month of the first imaging examinations, equally preventing the initiation of systemic treatment. The presented case shows how important is paying attention to the first symptoms, timely diagnosis of the disease and initiation of effective and targeted therapy in patients with SCLC.
References
Sarah Sharman Moser, Jair Bar, Inna Kan, et al. Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes. Curr. Oncol. 2021, 28(1); https://doi.org/10.3390/curroncol28010036
Society AC. Cancer Facts & Figures 2019 Atlanta, GA. Available online: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
Byers, L.A.; Rudin, C.M. Small cell lung cancer: Where do we go from here? Cancer 2015, 121; doi: 10.1002/cncr.29098
Reck, M.; Heigener, D.; Reinmuth, N. et al. Immunotherapy for small-cell lung cancer: Emerging evidence. Future Oncol. 2016 https://doi.org/10.2217/fon-2015-0012
Esposito G, Palumbo G, Carillio G, et al. Immunotherapy in Small Cell Lung Cancer. Cancers (Basel). 2020 Sep 4;12(9):2522. doi: 10.3390/cancers12092522
Gaspar LE, McNamara EJ, Gay EG et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012 Mar;13(2):115-22. doi: 10.1016/j.cllc.2011.05.008
Lara PN Jr, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061
Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6.
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 Feb 20;39(6):619-630.
Mansfield AS, Każarnowicz A, Karaseva N et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020 Feb;31(2):310-317.
Horn L, Mansfield AS, Szczęsna A et al. IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229.
Früh M, De Ruysscher D, Popat S, et al. ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6: vi99–v105, doi: 10.1093/annonc/mdt178
Dómine M, Moran T, Isla D, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol. 2020; 22(2): 245–255, doi: 10.1007/s12094-020-02295-w
A.-M.C. Dingemans, M. Früh, A. Ardizzoni, et. al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up; April 2021, doi :https://doi.org/10.1016/j.annonc.2021.03.207
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Aleksandra Łomża, Anna Rodzajewska, Magda Kowaleczko, Łukasz Łaba, Izabela Chmielewska, Janusz Milanowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1289
Number of citations: 0
